Researchers at the University of Pretoria have unveiled a revolutionary handheld device that could redefine tuberculosis detection worldwide. The MARTI (mycolate antibody real-time immunoassay) tool delivers results in 30 minutes using just one drop of blood, eliminating the need for hazardous sputum samples and lengthy lab processes.
With TB claiming over 1.2 million lives globally in 2024, this innovation addresses critical gaps in current diagnostics. Traditional methods requiring sputum analysis often take weeks, delaying treatment and increasing infection risks in healthcare settings.
"Our blood-based test detects immune responses to active infections while protecting patients and medical staff from exposure," explained Carl Baumeister of MARTI TB Diagnostics. The portable device enables single-visit testing, particularly valuable in high-transmission environments like mines and prisons where TB prevalence remains acute.
Professor Jan Verschoor emphasized the human impact: "20% of TB victims die undiagnosed. Rapid screening tools could prevent countless preventable deaths while reducing the disease's $12 billion annual economic burden through earlier intervention."
As clinical trials progress, global health organizations monitor this South African innovation that combines medical necessity with practical design – potentially transforming TB management across Asia's high-burden regions and beyond.
